Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CD70-IL-21 immunocytokine
- Development stage
- Preclinical
- Lead developer
- Fox Chase Cancer Center
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
This anti-CD70-IL-21 immunocytokine is a novel engineered fusion protein consisting of a humanized anti-CD70 monoclonal antibody fused to interleukin-21 (IL-21). Developed by researchers at the Fox Chase Cancer Center, it is designed to target clear cell renal cell carcinoma (ccRCC), where CD70 is highly overexpressed. The IL-21 portion has been modified via site-directed mutagenesis to disrupt heparin binding, which improves target specificity and pharmacokinetic properties while reducing off-target toxicity. The molecule acts by simultaneously binding CD70 on tumor cells and activating the IL-21 receptor (IL-21R) on immune cells, thereby enhancing antibody-dependent cellular cytotoxicity (ADCC) and preventing NK cell exhaustion. Preclinical studies in humanized mouse models have demonstrated significant anti-tumor activity against CD70-positive tumors.
- Other names
- humanized anti-CD70-IL-21 fusion antibodyIL-21-based immunocytokineIL21-based immunocytokineIL 21-based immunocytokine
02
Targets
CD70 (Cluster of Differentiation 70)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)IL21R (Interleukin-21 receptor)
Beyond the preview
Go deeper on anti-CD70-IL-21 immunocytokine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CD70-IL-21 immunocytokine.